0B68 Kelly, W. Kevin - Thomas Jefferson University - Thomas Jefferson University
Dr. Kelly

W. Kevin Kelly, DO

Contact Dr. Kelly

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
  2. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
  3. Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer
  4. An internet intervention for management of uncertainty during active surveillance for prostate cancer
  5. New therapies for castration-resistant prostate cancer: Efficacy and safety
  6. Epothilones in prostate cancer
  7. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer
  8. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
  9. The needs for men undergoing active surveillance (AS) for prostate cancer: Results of a focus group study
  10. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy
  11. Redefining hormone resistance in prostate cancer
  12. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials
  13. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer
  14. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
  15. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
  16. TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality
  17. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer
  18. Editorial Comment
  19. Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy
  20. Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy